United Laboratories International Holdings Ltd
HKEX:3933
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6.62
12.34
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
United Laboratories International Holdings Ltd
Total Current Assets
United Laboratories International Holdings Ltd
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Total Current Assets
¥15.1B
|
CAGR 3-Years
17%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Total Current Assets
HK$8.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
16%
|
CAGR 10-Years
16%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Total Current Assets
¥25.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
14%
|
|
|
C
|
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
|
Total Current Assets
¥20.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
27%
|
|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Total Current Assets
HK$197.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Total Current Assets
$1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
28%
|
CAGR 10-Years
27%
|
|
United Laboratories International Holdings Ltd
Glance View
United Laboratories International Holdings Ltd. has carved a significant niche in the global pharmaceutical industry, primarily through its prowess in producing antibiotic finished products and intermediates. Headquartered in Hong Kong, the company operates a diversified business model that spans manufacturing, marketing, and distribution of a wide range of pharmaceutical products. United Laboratories has established robust production facilities in China, positioning itself as one of the leading producers of antibiotics like amoxicillin and ampicillin. These products are vital to combating infections and are critical components in healthcare systems worldwide. The company's vertically integrated operations, coupled with its strategic focus on research and development, enable it to maintain cost efficiency while innovating continuously within its drug portfolio. The company's revenue mechanism is firmly rooted in its extensive distribution network and expansive market reach, which traverse not only the domestic markets but also international territories in North America, Europe, and Asia. United Laboratories leverages its strong brand presence and economies of scale to offer competitive pricing, enhancing its market penetration. Furthermore, it capitalizes on favorable regulatory frameworks in emerging markets, creating a tapestry of growth opportunities. The company's business strategy is also marked by its commitment to quality and adherence to stringent production standards, essential for maintaining trust and reliability among healthcare providers. Through these strategic channels, United Laboratories International Holdings Ltd. sustains its growth and profitability in the dynamic pharmaceutical landscape.
See Also
What is United Laboratories International Holdings Ltd's Total Current Assets?
Total Current Assets
15.1B
CNY
Based on the financial report for Jun 30, 2024, United Laboratories International Holdings Ltd's Total Current Assets amounts to 15.1B CNY.
What is United Laboratories International Holdings Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
11%
Over the last year, the Total Current Assets growth was 15%. The average annual Total Current Assets growth rates for United Laboratories International Holdings Ltd have been 17% over the past three years , 15% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet
